ijerph-logo

Journal Browser

Journal Browser

Advances in Alzheimer’s Disease and Healthy Aging

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Aging".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 3035

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacology, Toxicology and Medicinal Chemistry, University of Barcelona, 08007 Barcelona, Spain
Interests: neuroscience; behavior; aging; neurodegeneration; Alzheimer’s disease; epigenetics; mice; C. elegans; bioinformatics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Department of Cellular and Molecular Biology, University of Guadalajara, Guadalajara 44160, Mexico
Interests: aging; neuroscience; high-fat diet; cognitive decline; nutrition; lifestyle; SAMP8

Special Issue Information

Dear Colleagues,

Age-related cognitive decline—especially memory impairment—is one of the most prevalent consequences of growing older. The severity of age-related cognitive decline predisposes to neurodegenerative diseases like Alzheimer’s disease (AD). The molecular mechanisms of age-related cognitive decline and AD are considered to be multifactorial, and implicate the interaction of genetics and environmental factors (nutrition and pollutants, among others), acting as susceptibility factors or triggers that promote brain injury accumulation due to their chronicity during aging.

Although the main neuropathological hallmarks such as amyloid plaques and tau pathology are well-described, the causes of AD remain unknown, and no preventive or curative treatments are available. The treatments are currently divided into acetylcholinesterase inhibitors (AChEIs), and an antagonist of the N-methyl-D-aspartic (NMDA) receptor. Nevertheless, those drugs can only relieve symptoms for a short time, and cannot delay the progression of AD. Recent failures and the limited therapeutics in phase III suggest that it is time to consider new and alternative AD treatment strategies.

Thus, this Special Issue seeks to gather high-quality original research papers and review articles addressing recent advances focused on AD treatments that influence aging through pharmacological or non-pharmacological interventions (environmental enrichment (EE), exercise, meditation, yoga, etc.) and will focus on new insights into cellular, molecular, and cognitive changes that underlie healthy aging and/or the progression of AD pathology.

Dr. Christian Griñán-Ferré
Dr. Verónica Palomera-Avalos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aging
  • cognitive decline
  • Alzheimer’s disease
  • neurodegeneration
  • drug discovery
  • non-pharmacological interventions
  • pharmacological interventions
  • neuroscience

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 3089 KiB  
Article
Investigation of Potential Drug Targets for Cholesterol Regulation to Treat Alzheimer’s Disease
by Marina Passero, Tianhua Zhai and Zuyi Huang
Int. J. Environ. Res. Public Health 2023, 20(13), 6217; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph20136217 - 24 Jun 2023
Cited by 2 | Viewed by 1977
Abstract
Despite extensive research and seven approved drugs, the complex interplay of genes, proteins, and pathways in Alzheimer’s disease remains a challenge. This implies the intricacies of the mechanism for Alzheimer’s disease, which involves the interaction of hundreds of genes, proteins, and pathways. While [...] Read more.
Despite extensive research and seven approved drugs, the complex interplay of genes, proteins, and pathways in Alzheimer’s disease remains a challenge. This implies the intricacies of the mechanism for Alzheimer’s disease, which involves the interaction of hundreds of genes, proteins, and pathways. While the major hallmarks of Alzheimer’s disease are the accumulation of amyloid plaques and tau protein tangles, excessive accumulation of cholesterol is reportedly correlated with Alzheimer’s disease patients. In this work, protein-protein interaction analysis was conducted based upon the genes from a clinical database to identify the top protein targets with most data-indicated involvement in Alzheimer’s disease, which include ABCA1, CYP46A1, BACE1, TREM2, GSK3B, and SREBP2. The reactions and pathways associated with these genes were thoroughly studied for their roles in regulating brain cholesterol biosynthesis, amyloid beta accumulation, and tau protein tangle formation. Existing clinical trials for each protein target were also investigated. The research indicated that the inhibition of SREBP2, BACE1, or GSK3B is beneficial to reduce cholesterol and amyloid beta accumulation, while the activation of ABCA1, CYP46A1, or TREM2 has similar effects. In this study, Sterol Regulatory Element-Binding Protein 2 (SREBP2) emerged as the primary protein target. SREBP2 serves a pivotal role in maintaining cholesterol balance, acting as a transcription factor that controls the expression of several enzymes pivotal for cholesterol biosynthesis. Novel studies suggest that SREBP2 performs a multifaceted role in Alzheimer’s disease. The hyperactivity of SREBP2 may lead to heightened cholesterol biosynthesis, which suggested association with the pathogenesis of Alzheimer’s disease. Lowering SREBP2 levels in an Alzheimer’s disease mouse model results in reduced production of amyloid-beta, a major contributor to Alzheimer’s disease progression. Moreover, its thoroughly analyzed crystal structure allows for computer-aided screening of potential inhibitors; SREBP2 is thus selected as a prospective drug target. While more protein targets can be added onto the list in the future, this work provides an overview of key proteins involved in the regulation of brain cholesterol biosynthesis that may be further investigated for Alzheimer’s disease intervention. Full article
(This article belongs to the Special Issue Advances in Alzheimer’s Disease and Healthy Aging)
Show Figures

Figure 1

Back to TopTop